MORRISVILLE, N.C., April 02, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today that Dr. Roger Jeffs, Chief Executive Officer, and Micheal Kaseta, Chief Operating Officer and Chief Financial Officer, will provide an overview and update on the company's business during a fireside chat session at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024,... Read More

On March 28, Judge Andrews removed the injunction issued in the Original Hatch Waxman Litigation On March 29, Judge Bates denied United Therapeutics’ motion for temporary restraining order and preliminary injunction in separate litigation filed by United Therapeutics against the FDA On March 31, regulatory exclusivity expired for Tyvaso® in treating PH-ILD MORRISVILLE, N.C., April 01, 2024 (GLOBE NEWSWIRE) -- Liquidia... Read More

Preparing to launch YUTREPIA™ (treprostinil) inhalation powder upon final FDA approval Federal Circuit rejected request by United Therapeutics for rehearing of earlier decision finding ‘793 Patent invalid Advancing industry leading portfolio for inhaled treprostinil with YUTREPIA and sustained-release program L606 Company to host webcast today at 8:30 a.m. ET MORRISVILLE, N.C., March 13, 2024 (GLOBE NEWSWIRE) -- Liquidia... Read More

MORRISVILLE, N.C., March 06, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its full year 2023 financial results on Wednesday, March 13, 2024. The company will host a webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update. The webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations . A... Read More

MORRISVILLE, N.C., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) today announced that the Company will present data from the L606 clinical program at the Pulmonary Vascular Research Institute (PVRI) 2024 Annual Congress to be held January 31 through February 3, 2024, in London, England. L606 is an investigational, sustained-release formulation of treprostinil administered... Read More

MORRISVILLE, N.C., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (the Company) (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) provided an update on its review of the New Drug Application (NDA) for YUTREPIA™ (treprostinil) inhalation powder to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The FDA informed the... Read More

MORRISVILLE, N.C., Jan. 19, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today updates and promotions to its operations leadership in advance of the potential approval and launch of YUTREPIA™ (treprostinil) inhalation powder. Michael Kaseta, Chief Financial Officer (CFO), has added the role of Chief Operating Officer (COO) to his responsibilities effective on January 15,... Read More

Seeks dismissal of all claims related to ‘793 patent based on prior findings of invalidity which have been affirmed by the Federal Circuit Requests declaration that ‘327 patent is not infringed, is invalid and is unenforceable Files counterclaims asserting United Therapeutics failed to properly disclose prior art references and additional material information in its prosecution of the ‘327 patent that would have rendered the... Read More

Enrolled first PH-ILD patient in the open-label ASCENT study of YUTREPIA Confirmed with FDA that a single pivotal efficacy trial with L606 will support PAH and PH-ILD indications MORRISVILLE, N.C., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) provided an update today on the clinical progress of its pipeline programs to treat pulmonary arterial hypertension (PAH) and... Read More

Agreed to $75.0 million sale of common stock to fund affiliated with Patient Square Capital in a private placement Additional advance of $25.0 million from HealthCare Royalty under current financing agreement MORRISVILLE, N.C., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today that the Company has entered into agreements for an additional $100 million in capital... Read More

MORRISVILLE, N.C., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today that Dr. Roger Jeffs, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, beginning at approximately 11:15 a.m. Pacific Time (2:15 p.m. Eastern Time) at the Westin St. Francis in San Francisco, California. Access to a live,... Read More

Liquidia will pursue final FDA approval for YUTREPIA™ (treprostinil) inhalation Liquidia will immediately request that District Court set aside injunction tied to ‘793 patent MORRISVILLE, N.C., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced that the U.S. Court of Appeals for the Federal Circuit (Federal Circuit) today affirmed the earlier decision by the Patent Trial... Read More

MORRISVILLE, N.C., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it has priced an underwritten public offering of 3,491,620 shares of common stock at a public offering price of $7.16 for total gross proceeds of approximately $25.0 million, before deducting underwriting discounts and commissions and expenses payable by Liquidia. The offering is expected to close on December 14,... Read More

Oral arguments in appeal of ‘793 PTAB decision set for December 4, 2023 PDUFA goal date to add PH-ILD indication to YUTREPIA label is January 24, 2024 Hired sales force in preparation of potential positive legal and regulatory outcomes MORRISVILLE, N.C., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) today reported financial results for the third quarter ended September 30,... Read More

MORRISVILLE, N.C., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its third quarter 2023 financial results on Tuesday, November 7, 2023. The company will host a webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update. The webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations.... Read More

Sets PDUFA goal date of January 24, 2024 If approved, YUTREPIA would be indicated for treatment of both PAH and PH-ILD MORRISVILLE, N.C., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (the Company) (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) accepted for review the Company’s amendment to the tentatively approved new drug application (NDA) for YUTREPIA™ (treprostinil) inhalation... Read More

Asserts ‘793 patent in new litigation filed under Hatch-Waxman Act in response to Liquidia’s amendment to its NDA to add PH-ILD to YUTREPIA™ label Litigation is tied to same ‘793 patent previously ruled invalid by Patent Trial and Appeal Board (PTAB) MORRISVILLE, N.C., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company), announced today that United Therapeutics Corporation (UTHR)... Read More

MORRISVILLE, N.C., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) today reported financial results for the second quarter ended June 30, 2023. The Company will host a webcast at 8:30 a.m. ET to discuss the financial results and provide a corporate update. Dr. Roger Jeffs, Liquidia’s Chief Executive Officer, said: “This quarter saw Liquidia significantly advance our mission to... Read More

MORRISVILLE, N.C., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its second quarter 2023 financial results on Thursday, August 10, 2023. The company will host a webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update. The webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations.... Read More

No new clinical data is required to add PH-ILD indication as per FDA correspondence Recertified that YUTREPIA does not infringe any valid patents listed in the Orange Book for Tyvaso Preparing for potential launch of YUTREPIA between end of 2023 to mid-2024 MORRISVILLE, N.C., July 27, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today the submission of an amendment to the tentatively approved new... Read More

Infringement case now only focused on ‘793 patent, previously found to be invalid by PTAB in IPR Federal Circuit expected to hear appeal of PTAB decision in late 4th quarter 2023 to early 2024 If PTAB decision affirmed, Liquidia will request final regulatory approval for YUTREPIA™ (treprostinil) inhalation powder MORRISVILLE, N.C., July 24, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the... Read More

Liquidia exclusively licenses North American rights to L606, an inhaled formulation of treprostinil administered twice-daily with a short duration, next-generation nebulizer Liquidia funds $10 million upfront payment from finance agreement with HealthCare Royalty Pharmosa to receive up to $215 million in development and sales milestones for PAH and PH-ILD indications, $10 million for each additional approved indication and... Read More

MORRISVILLE, N.C., May 31, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (the Company) (NASDAQ: LQDA) announced today that Mr. Roger Jeffs, Chief Executive Officer, and Mr. Michael Kaseta, Chief Financial Officer, will provide an update on the Company's business during a fireside chat at the 2023 Jefferies Healthcare Conference taking place June 7-9, 2023, in New York City, NY. The presentation is scheduled to begin Friday,... Read More

MORRISVILLE, N.C., May 19, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced the Company will present data related to the investigational use of YUTREPIA™ (treprostinil) inhalation powder at the 2023 American Thoracic Society (ATS) International Conference, taking place May 19-24, 2023, in Washington, D.C. Thematic Poster Session: B64 - The Multiple Components of... Read More

MORRISVILLE, N.C., May 04, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) today reported financial results for the first quarter ended March 31, 2023. The Company will host a webcast at 8:30 a.m. ET to discuss the financial results and provide a corporate update. Roger Jeffs, Liquidia’s Chief Executive Officer, said: “We have heard from the physician community about the increasing... Read More

MORRISVILLE, N.C., May 02, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Mr. Michael Kaseta, Chief Financial Officer, will provide an update on the company's business during a fireside chat at the BofA Securities 2023 Health Care Conference in Las Vegas, Nevada. The presentation is scheduled to begin Tuesday, May 9, 2023 at 12:35 p.m. Eastern Time (9:35 a.m. Pacific Time) and can be... Read More

MORRISVILLE, N.C., April 27, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its first quarter 2023 financial results on Thursday, May 4, 2023. The company will host a webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update. The webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations . A... Read More

MORRISVILLE, N.C., April 11, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Mr. Michael Kaseta, Chief Financial Officer, will provide an overview and update on the company's business during a fireside chat session at the 22nd Annual Needham Virtual Healthcare Conference. The presentation is scheduled to begin Tuesday, April 18, 2023 at 11:00 a.m. Eastern Standard Time and can be accessed... Read More

New agreement supersedes the collaboration agreement entered in 2012 GSK retains non-exclusive right to use PRINT for pre-clinical research for inhaled delivery Liquidia can apply PRINT to any inhaled application other than identified GSK proprietary molecules MORRISVILLE, N.C., April 03, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today that it has entered a new,... Read More

Clarified path to potential launch YUTREPIA upon resolution of litigation in late-2023 to mid-2024 Fortified financial position through 2024 Company to host webcast today at 8:30 a.m. ET MORRISVILLE, N.C., March 16, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today reported financial results for the full year ended December 31, 2022. The Company will host a webcast at 8:30 a.m.... Read More

MORRISVILLE, N.C., March 09, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its full year 2022 financial results on Thursday, March 16, 2023. The company will host a webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update. The webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations . A... Read More

PTAB rejects UTHR’s request for rehearing of its decision in the inter partes review of the ‘793 Patent (‘793 IPR) PTAB clarified grounds upon which it based its finding that the cited publications, which invalidated the claims, constituted prior art Company reaffirms expectation of legal resolution in late 2023 or the first half of 2024 MORRISVILLE, N.C., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA)... Read More

MORRISVILLE, N.C., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced the grant of inducement stock options exercisable for an aggregate of 10,000 shares of Liquidia’s common stock to newly hired non-executive employees under the Liquidia Corporation 2022 Inducement Plan (the “ Inducement Plan ”). Each stock option was granted as an inducement material to the grantee’s acceptance of... Read More

Extends cash-runway through at least 2024 Provides flexibility to accelerate launch preparations timed with success in litigation MORRISVILLE, N.C., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today that it has entered into a Revenue Interest Financing Agreement with HealthCare Royalty (HCRx) for a total investment amount of up to $100 million. Liquidia intends to... Read More